These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 21439443)

  • 41. MRI as an outcome in multiple sclerosis clinical trials.
    Daumer M; Neuhaus A; Morrissey S; Hintzen R; Ebers GC
    Neurology; 2009 Feb; 72(8):705-11. PubMed ID: 19073945
    [TBL] [Abstract][Full Text] [Related]  

  • 42. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
    Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
    Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [The technology of treatment of multiple sclerosis with long-term immunomodulating drugs (disease modifying drugs--DMD)--beta-interferons and glatiramer-acetate].
    Federal service on surveillance in healthcare and social development (Roszdravnadzor)
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):86-92. PubMed ID: 21916162
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The current landscape and unmet needs in multiple sclerosis.
    Markowitz CE
    Am J Manag Care; 2010 Sep; 16(8 Suppl):S211-8. PubMed ID: 20873945
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment of early onset multiple sclerosis with suboptimal dose of interferon beta-1a.
    Pakdaman H; Fallah A; Sahraian MA; Pakdaman R; Meysamie A
    Neuropediatrics; 2006 Aug; 37(4):257-60. PubMed ID: 17177154
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Therapeutic decision making in a new drug era in multiple sclerosis.
    Keegan BM
    Semin Neurol; 2013 Feb; 33(1):5-12. PubMed ID: 23709208
    [TBL] [Abstract][Full Text] [Related]  

  • 47. New and emerging disease modifying therapies for multiple sclerosis.
    Saidha S; Eckstein C; Calabresi PA
    Ann N Y Acad Sci; 2012 Jan; 1247():117-37. PubMed ID: 22224673
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Medication use in a large international sample of people with multiple sclerosis: associations with quality of life, relapse rate and disability.
    Jelinek GA; Weiland TJ; Hadgkiss EJ; Marck CH; Pereira N; van der Meer DM
    Neurol Res; 2015 Aug; 37(8):662-73. PubMed ID: 25905471
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Short-term suboptimal response criteria for predicting long-term non-response to first-line disease modifying therapies in multiple sclerosis: A systematic review and meta-analysis.
    Río J; Ruiz-Peña JL
    J Neurol Sci; 2016 Feb; 361():158-67. PubMed ID: 26810535
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions.
    Banwell B; Ghezzi A; Bar-Or A; Mikaeloff Y; Tardieu M
    Lancet Neurol; 2007 Oct; 6(10):887-902. PubMed ID: 17884679
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [New and emerging treatments for multiple sclerosis].
    Louapre C; Maillart É; Papeix C; Lubetzki C
    Med Sci (Paris); 2013 Dec; 29(12):1105-10. PubMed ID: 24356140
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Diagnosis and treatment of multiple sclerosis.
    Myhr KM
    Acta Neurol Scand Suppl; 2008; 188():12-21. PubMed ID: 18439216
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Placebo? no thanks, it might be bad for me!
    Garattini S; Bertelé V; Banzi R
    Eur J Clin Pharmacol; 2013 Mar; 69(3):711-4. PubMed ID: 22983310
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The search for a balance between short and long-term treatment outcomes in multiple sclerosis.
    Baumhackl U
    J Neurol; 2008 Mar; 255 Suppl 1():75-83. PubMed ID: 18317679
    [TBL] [Abstract][Full Text] [Related]  

  • 55. New therapeutic approaches for multiple sclerosis.
    De Jager PL; Hafler DA
    Annu Rev Med; 2007; 58():417-32. PubMed ID: 17217332
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunotherapy of multiple sclerosis: the state of the art.
    Karussis D
    BioDrugs; 2013 Apr; 27(2):113-48. PubMed ID: 23423844
    [TBL] [Abstract][Full Text] [Related]  

  • 57. FDA-approved preventative therapies for MS: first-line agents.
    Kita M
    Neurol Clin; 2011 May; 29(2):401-9. PubMed ID: 21439449
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Pathogenetic treatment of multiple sclerosis: the present and the future].
    Boĭko AN; Stoliarov ID; Sidorenko TV; Kulakova OV; Kol'iak EV; Petrov AM; Il'ves AG; Nikiforova IG; Favorova OO; Gusev EI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(7 Suppl 2):90-9. PubMed ID: 19894313
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Novel therapeutics in multiple sclerosis management: clinical applications.
    Leist T; Hunter SF; Kantor D; Markowitz C
    Am J Med; 2014 Jan; 127(1):S2. PubMed ID: 24384114
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Balancing Early Aggression Against Risk of Progression in Multiple Sclerosis.
    Duquette P; Giacomini PS; Bhan V; Hohol M; Schecter R
    Can J Neurol Sci; 2016 Jan; 43(1):33-43. PubMed ID: 26611431
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.